Statistical evidence from meta-analysis of VIVIAD and VIVA-MIND enables efficient design of Phase 2b study in diabetic kidney disease (DKD), ideally suited to evaluate varoglutamstat in the intended ...

(NASDAQ: REGN) today announced that the European Commission (EC) has granted conditional marketing approval of Lynozyfic™ (linvoseltamab) to treat adults with relapsed and refractory (R/R) multiple ...